Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP690324.RAbMVRxFjkMz6a5LOEMMtcc4Ty9xuEHFN3blG_-wD837g130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP690324.RAbMVRxFjkMz6a5LOEMMtcc4Ty9xuEHFN3blG_-wD837g130_assertion type Assertion NP690324.RAbMVRxFjkMz6a5LOEMMtcc4Ty9xuEHFN3blG_-wD837g130_head.
- NP690324.RAbMVRxFjkMz6a5LOEMMtcc4Ty9xuEHFN3blG_-wD837g130_assertion description "[SEMG-1 is expressed in nearly half of patients with early CLL and may be a target for further investigations into its use for immunotherapy of early CLL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP690324.RAbMVRxFjkMz6a5LOEMMtcc4Ty9xuEHFN3blG_-wD837g130_provenance.
- NP690324.RAbMVRxFjkMz6a5LOEMMtcc4Ty9xuEHFN3blG_-wD837g130_assertion evidence source_evidence_literature NP690324.RAbMVRxFjkMz6a5LOEMMtcc4Ty9xuEHFN3blG_-wD837g130_provenance.
- NP690324.RAbMVRxFjkMz6a5LOEMMtcc4Ty9xuEHFN3blG_-wD837g130_assertion SIO_000772 19241194 NP690324.RAbMVRxFjkMz6a5LOEMMtcc4Ty9xuEHFN3blG_-wD837g130_provenance.
- NP690324.RAbMVRxFjkMz6a5LOEMMtcc4Ty9xuEHFN3blG_-wD837g130_assertion wasDerivedFrom befree-20150227 NP690324.RAbMVRxFjkMz6a5LOEMMtcc4Ty9xuEHFN3blG_-wD837g130_provenance.
- NP690324.RAbMVRxFjkMz6a5LOEMMtcc4Ty9xuEHFN3blG_-wD837g130_assertion wasGeneratedBy ECO_0000203 NP690324.RAbMVRxFjkMz6a5LOEMMtcc4Ty9xuEHFN3blG_-wD837g130_provenance.